As researchers home in on the genetic underpinnings of disease, the National Institutes of Health (NIH) is awarding a dozen grants to scientists who are exploring ways to combine genomic test information with electronic health records to improve care for patients.
Over the last decade, the amount of genomic sequencing data available has doubled every 7 months, rivaling Twitter and YouTube for data storage demands and analysis capacity. But the deluge of DNA sequencing data is just beginning, and the exabyte-sized tsunami to come will require a new approach to the technology used to store the data--and learn from it, according to experts from the University of Illinois and Cold Spring Harbor Laboratory.
Apple has designs on the DNA sequencing sector. The tech giant is reportedly working with researchers to make 23andMe-style DNA sequencing spit kits part of ResearchKit, the platform that turned every iPhone user into a potential study participant.
Roche snatched up DNA sequencing outfit Bina Technologies for an undisclosed sum, continuing its M&A winning streak and expanding its diagnostics footprint.
While early adopters of Illumina's $1,000 genome machine the HiSeq X Ten have been testing the system for months, researchers from less wealthy organizations have had no access to the technology. In a limited way that changed this week, when the Garvan Institute of Medical Research, DNAnexus and AllSeq teamed up to share data from a HiSeq X Ten.
The National Institutes of Health (NIH) has awarded $14.5 million in eight grants to researchers working to develop high quality and low cost DNA sequencing. The grants are each for two to four years and are awarded through the Advanced DNA Sequencing Technology program of the National Human Genome Research Institute, a part of NIH.
After failing to buy Illumina in 2012 and deciding to close its 454 Life Sciences sequencing unit last year, Roche has been looking for technologies to strengthen its diagnostic business.
Having seen off Roche's 454 Life Sciences and established a big lead over its remaining rivals, Illumina now faces a new challenger for the DNA sequencing market.
Enzymatics is expanding its offerings in the DNA sequencing market with the buyout of startup ArcherDx, which provides kits and software for evaluating cancer treatment. Add up the cash, Enzymatics equity and potential milestone fees in the deal, and the buyout could be worth up to $50 million.
Roche has unveiled a software update for improving DNA sequencing studies, for which advances in information technology have become crucial to improving accuracy and speed of 'omics data analysis.